Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISLA-6181 is a small molecule antiviral candidate being developed by Island Pharmaceuticals (formerly Isla Pharmaceuticals). Currently in the IND-enabling stage, it is characterized as a host-targeting antiviral (HTA) designed to treat various viral infections, potentially including flaviviruses such as Dengue and Zika. As a next-generation HTA, it aims to inhibit host cell proteins that viruses exploit for replication, thereby providing a broad-spectrum therapeutic approach with a higher barrier to viral resistance compared to direct-acting antivirals. The drug's mechanism involves blocking the nuclear transport of viral proteins, which prevents the virus from suppressing the host's innate immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ISLA-6181.